luristem was founded in 2001 by Shai Meretzki of the Technion, who made use of a stem cell patent which was developed during his Ph.D. studies at The Rappaport Faculty Of Medicine, Technion, under the supervision of Dr. Shosh Merchav, together with Professors Dov Zipori and Avinoam Kadouri from the Weizmann Institute of Science.
In 2003, the NASDAQ-listed shell company A1 Software acquired all shares and patents belonging to Pluristem and changed its name to Pluristem Life Systems.[6][7] In 2007 the name was changed again, this time to Pluristem Therapeutics Inc.[4] Pluristem’s shares are traded on the NASDAQ exchange and the Tel Aviv Stock Exchange, as well as on the Frankfurt Stock Exchange.
In December 2020, the Genesis Prize and Start-up Nation Central named Pluri as one of the winners in a competition among Israeli high-tech and biotechnology companies.
In July 2022, the company changed its name from Pluristem Therapeutics to Pluri Inc. and its ticker symbol to PLUR from PSTI.